Oral fludara of high-purity formulation with quick release of active ingredient
This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
1. A quick-release tablet formulation that comprises
1 to 100 mg of the active ingredient fludarabine phosphate having a purity of >99.19%,
lactose monohydrate,
colloidal silicon dioxide,
microcrystalline cellulose,
sodium carboxymethyl cellulose, and
magnesium stearate,
wherein said formulation releases fludarabine phosphate with a quick release profile, and
wherein the contaminants in the fludarabine-phosphate do not exceed:
0.02% 2-fluoro-9-(β-D-arabinofuranosyl)-9H-purine-6-amine,
0.12% 6-amino-9(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-2-ol,
0.02% 2-fluoro-9H-purine-6-amine,
0.02% 6-amino-9H-purin-2-ol,
0.05% 2-fluoro-9-(5-O-phosphono-β-D-ribofuranosyl)-9H-purine-6-amine,
0.1% 9-(3,5-O-diphosphono-β-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine,
0.1% 9-(2,5-O-diphosphono-β-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine,
0.02% 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purine-6-amine,
0.06% 2-ethoxy-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purine-6-amine,
0.02% 2-(6-amino-9H-purin-2-yl)-9-(5-O-phosphono-β-D-arabinofuranosyl)- 9H-purine-6-amine and O,O′-bis[2-(6-amino-2-fluoro-9H-purin-9-yl)-5-deoxy-α-D- arabinofuranos-5-yl]-phosphate,
0.1% 9-(2-chloro-2-deoxy-5-phosphono-β-D-arabinofuranosyl)-2-fluoro-9H-purine- 6-amine, and
0.1% 9-(2,5-anhydro-β-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine.
2. A quick-release tablet formulation according to claim 1 , which comprises 1–70 mg of the active ingredient fludarabine phosphate having a purity of >99.19%,
50–100 mg of lactose monohydrate,
0.1–5 mg of colloidal silicon dioxide,
40–100 mg of microcrystalline cellulose,
1–10 mg of sodium carboxymethyl cellulose and
0.5–10 mg of magnesium stearate.
3. A quick-release tablet formulation according to claim 1 , which comprises 1–50 mg of the active ingredient fludarabine phosphate having a purity of >99.19%,
60–90 mg of lactose monohydrate,
0.5–1 mg of colloidal silicon dioxide,
50–90 mg of microcrystalline cellulose,
2.5–5 mg of sodium carboxymethyl cellulose and
1–3 mg of magnesium stearate.
4. A quick-release tablet formulation according to claim 1 , which comprises 10 mg of the active ingredient fludarabine phosphate having a purity of >99.19%,
74.75 mg of lactose monohydrate,
0.75 mg of colloidal silicon dioxide,
60.00 mg of microcrystalline cellulose,
3.00 mg of sodium carboxymethyl cellulose and
1.5–2.00 mg of magnesium stearate.
5. A quick-release tablet formulation according to claim 1 , which comprises the active ingredient fludarabine phosphate having a purity of >99.37%.
6. A quick-release tablet formulation according to claim 1 , which comprises the active ingredient fludarabine phosphate having a purity of >99.57%.
7. A quick-release tablet formulation according to claim 1 , which comprises the active ingredient fludarabine phosphate having a purity of >99.80%.
8. A quick-release tablet formulation according to claim 1 , which comprises the active ingredient fludarabine phosphate having a purity of >99.85%.
9. A quick-release tablet formulation according to claim 1 , wherein the tablet has a core encased by a coating comprising:
1–5 mg of hydroxypropyl methyl cellulose,
0.1–1 mg of talc,
0.1–5 mg of titanium dioxide,
0.01–0.1 mg of yellow iron oxide pigment and
0.01–0.1 mg of red iron oxide pigment.
10. A quick-release tablet formulation according to claim 1 , wherein the tablet has a core encased by a coating, comprising:
1–3 mg of hydroxypropyl methyl cellulose,
0.1–0.8 mg of talc,
0.1–2 mg of titanium dioxide,
0.01–0.05 mg of yellow iron oxide pigment and
0.01–0.05 mg of red iron oxide pigment.
11. A quick-release tablet formulation according to claim 1 , wherein the tablet has a core encased by a coating, comprising:
2.250 mg of hydroxypropyl methyl cellulose,
0.450 mg of talc,
1.187 mg of titanium dioxide,
0.036 mg of yellow iron oxide pigment and
0.036 mg of red iron oxide pigment.
12. A medication for treating cancer comprising a tablet formulation according to claim 1 .